Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Martiskainen, Hennaa; 1 | Helisalmi, Seppoa; 1 | Viswanathan, Jayashreea | Kurki, Mitjab; c | Hall, Anettea | Herukka, Sanna-Kaisaa | Sarajärvi, Timoa | Natunen, Teemua | Kurkinen, Kaisa M.A.a | Huovinen, Jaakkoa | Mäkinen, Petraa | Laitinen, Marjoa | Koivisto, Anne M.a | Mattila, Kari M.d | Lehtimäki, Terhod | Remes, Anne M.a | Leinonen, Villeb; c | Haapasalo, Annakaisaa | Soininen, Hilkkaa | Hiltunen, Mikkoa; e; *
Affiliations: [a] Institute of Clinical Medicine – Neurology, University of Eastern Finland, and Department of Neurology, Kuopio University Hospital, Kuopio, Finland | [b] Neurosurgery of NeuroCenter, Kuopio University Hospital, Kuopio, Finland | [c] Institute of Clinical Medicine – Neurosurgery, University of Eastern Finland, Kuopio, Finland | [d] Department of Clinical Chemistry, Fimlab Laboratories and School of Medicine, University of Tampere, Tampere, Finland | [e] Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
Correspondence: [*] Correspondence to: Mikko Hiltunen, PhD, Institute of Clinical Medicine – Neurology, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland. Tel.: +358 40 355 2014; Fax: +358 17 162048; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: Background:Several risk loci for Alzheimer's disease (AD) have been identified during recent years in large-scale genome-wide association studies. However, little is known about the mechanisms by which these loci influence AD pathogenesis. Objective:To investigate the individual and combined risk effects of the newly identified AD loci. Methods:Association of 12 AD risk loci with AD and AD-related cerebrospinal fluid (CSF) biomarkers was assessed. Furthermore, a polygenic risk score combining the effect sizes of the top 22 risk loci in AD was calculated for each individual among the clinical and neuropathological cohorts. Effects of individual risk loci and polygenic risk scores were assessed in relation to CSF biomarker levels as well as neurofibrillary pathology and different biochemical measures related to AD pathogenesis obtained from the temporal cortex. Results:Polygenic risk scores associated with CSF amyloid-β42 (Aβ42) levels in the clinical cohort, and with soluble Aβ42 levels and γ-secretase activity in the neuropathological cohort. The γ-secretase effect was independent of APOE. APOE-ε4 associated with CSF Aβ42 (p < 0.001) levels. For the other risk loci, no significant associations with AD risk or CSF biomarkers were detected after multiple testing correction. Conclusions:AD risk loci polygenically contribute to Aβ pathology in the CSF and temporal cortex, and this effect is potentially associated with increased γ-secretase activity.
Keywords: Alzheimer's disease, amyloid-β peptide, biomarker, cerebrospinal fluid, polygenic risk score, risk gene, tau protein
DOI: 10.3233/JAD-140777
Journal: Journal of Alzheimer's Disease, vol. 43, no. 2, pp. 565-573, 2015
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]